{"id":"W7117368559","doi":"10.1177/13524585251396433","title":"Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial","year":2025,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Multiple sclerosis; Clinical trial; Phase (matter); Phases of clinical research; Central nervous system disease; Fingolimod","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002646954,0.001660938,0.002411287,0.0003699413,0.0006353132,0.000996999,0.0008151329,0.002563475,0.009637579],"category_scores_gemma":[0.002899184,0.0006197291,0.001734095,0.0003633884,0.0008559537,0.001105731,0.0004254873,0.002011176,0.001097447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006610536,"about_ca_system_score_gemma":0.001222232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006392825,"about_ca_topic_score_gemma":0.001795358,"domain_scores_codex":[0.9989495,0.0006105875,0.00007884153,0.0001752991,0.00007803334,0.0001077858],"domain_scores_gemma":[0.9985232,0.0004244216,0.0004804186,0.00009645776,0.0001331315,0.0003424215],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9819724,0.004572637,0.0006472595,0.0009833362,0.0007770522,0.00003129799,0.00004757382,0.00006172595,0.001729519,0.00005057296,0.0005312107,0.008595374],"study_design_scores_gemma":[0.9606289,0.03657255,0.001624941,0.00004904652,0.0004365145,0.00002343319,0.00001300253,0.00007400862,0.000154462,0.00005807834,0.0003577975,0.000007207856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713765,0.009641848,0.0006639627,0.001230734,0.00055171,0.01171723,0.002266825,0.0001335416,0.002417712],"genre_scores_gemma":[0.9693329,0.004884735,0.002223017,0.002086798,0.0007605061,0.01517871,0.001510527,0.00002940198,0.003993376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009637579,"threshold_uncertainty_score":0.03224087,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1094303334317801,"score_gpt":0.3429658681211005,"score_spread":0.2335355346893204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}